Clinical trials: Urticaria

Hereditary Angioedema, Hereditary Angioedema Type I

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

• Terminated
• Age: 18 to 75 years
• Phase 2
• Results posted

This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE).

Conditions

Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II

Trial name

HAE CHAPTER-1 (NCT05047185)

Testing

Deucrictibant low dose, Deucrictibant high dose

Where

19 sites in United States, Austria and 7 more

Volunteers

34 people

Sponsor

Pharvaris Netherlands B.V.